RhoGAM® Brand Dosing

The dosing instructions for RhoGAM® Brand are clearly defined to ensure that patients are protected from Rh sensitization for the duration of pregnancy. RhoGAM® Brand dosing is aligned with the standards of both the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Blood Banks (AABB).

Precise Dosing Instructions

AVAILABLE IN TWO DOSAGE STRENGTHS

  • RhoGAM® 300 µg—For antenatal and postpartum use, second- and third-trimester pregnancy terminations, or transplacental hemorrhage1-3
  • MICRhoGAM® 50 µg—For use immediately after first-trimester pregnancy termination 3,4

WHEN TO ADMINISTER RhoGAM® Brand

  • At 28 weeks’ gestation5-8
  • Within 72 hours postpartum1
  • Following spontaneous or induced termination4
  • Following any event that could lead to transplacental hemorrhage (such as amniocentesis, chorionic villus sampling (CVS), percutaneous umbilical blood sampling (PUBS), or abdominal trauma)2

HOW OFTEN TO ADMINISTER RhoGAM® Brand

  • RhoGAM® Brand should be administered in 12-week intervals9

Severe systemic allergic reactions are extremely rare.3

References:

  1. RhoGAM® Ultra-Filtered PLUS Package Insert. Ortho Clinical Diagnostics.
  2. RhoGAM® Ultra-Filtered Marketing Authorization Application: Part IB1. Summary of Product Characteristics. Ortho Clinical Diagnostics. November 2000.
  3. Pollack W, Ascari WQ, Kochesky RJ, et al. Studies on Rh prophylaxis. 1. Relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion. 1971;11:333-339.
  4. Frigolette FD Jr, ed. Antepartum administration of Rh immune globulin: a guide to office procedure. Raritan, NJ: Ortho-Diagnostic Systems, Inc. 1983.
  5. Bowman JM, Chown B, Lewis M, et al. Rh isoimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc J. 1978;118:623-627.
  6. Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks’ gestation service program. Can Med Assoc J. 1978;118:627-630.
  7. Baskett TF, Parsons ML. Prevention of Rh(D) alloimmunization: a cost-benefit analysis. Can Med Assoc J. 1990;142;337-339.
  8. Bowman JM. Antenatal suppression of Rh alloimmunization. Clin Obstet Gynecol. 1991;34:296-303.
  9. Mintz PD. Rh Immune Globulin. In: Mintz PD, ed. Transfusion Therapy: Clinical Principles and Practice, 2nd Edition. Bethesda, MD: AABB Press; 2005.
  10. Freda VJ, Gorman JG, Pollack W, et al. Prevention of Rh hemolytic disease—ten years’ clinical experience with Rh immune globulin. N Engl J Med. 1975;292:1014-1016.
  11. Prevention of Rh D Alloimmunization. ACOG Practice Bulletin. Number 4, May 1999. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists.



Important Safety Information

RhoGAM® Brand is indicated for the prevention of Rh immunization, including during and after pregnancy and other obstetrical conditions or incompatible transfusion of Rh-positive blood.

RhoGAM® and MICRhoGAM® Ultra-Filtered PLUS Rho(D) Immune Globulin (Human) are made from human plasma. Since all plasma-derived products are made from human blood, they may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically the Creutzfeldt-Jakob disease (CJD) agent.

RhoGAM® and MICRhoGAM® are intended for maternal administration. Do not inject the newborn infant. Local adverse reactions may include redness, swelling, and mild pain at the site of injection and a small number of patients have noted a slight elevation in temperature. Patients should be observed for at least 20 minutes after administration. Hypersensitivity reactions include hives, generalized urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.

RhoGAM® and MICRhoGAM® contain a small quantity of IgA and physicians must weigh the benefit against the potential risks of hypersensitivity reactions. Patients who receive RhoGAM® and MICRhoGAM® for Rh-incompatible transfusion should be monitored by clinical and laboratory means due to the risk of a hemolytic reaction.

Click here for the RhoGAM® Brand Full Prescribing information